• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.24% Nasdaq Up0.16%

    More On PRAN


    Prana Biotechnology Limited (PRAN)

    -NasdaqCM
    0.90 Up 0.01(1.11%) 11:02AM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Prana Biotechnology Limited
    369 Royal Parade
    Level 2
    Parkville, VIC 3052
    Australia - Map
    Phone: 61 3 9349 4906
    Fax: 61 3 9348 0377
    Website: http://www.pranabio.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:N/A

    Business Summary 

    Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate is PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company was founded in 1997 and is based in Parkville, Australia.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Prana Biotechnology Limited

    Key Executives 
     PayExercised
    Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, 60
    Co-Founder, Exec. Chairman and Chief Exec. Officer
    395.00KN/A
    Ms. Kathryn Andrews B.Com, CPA,
    Chief Financial Officer
    63.00KN/A
    Ms. Dianne M. Angus , 55
    Chief Operating Officer
    247.00KN/A
    Mr. Phillip A. Hains , 56
    Company Sec.
    71.00KN/A
    Prof. Rudolph Emile Tanzi Ph.D.,
    Chief Scientific Advisor and Member of R&D Advisory Board
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.